Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9532012 | 0.90 | MAPT (0.53) | KMT2AMAPTNPSR1MEN1RAB9A | |
| SCHEMBL9528513 | 0.88 | MAPT (0.52) | KMT2AMAPTNPSR1MEN1RAB9A | |
| SCHEMBL27597146 | 0.88 | DHODH (0.53) | KMT2AMAPTNPSR1MEN1RAB9A | |
| SCHEMBL9687349 | 0.85 | MAPT (0.49) | KMT2AMAPTNPSR1MEN1RAB9A | |
| SCHEMBL5952505 | 0.85 | MAPT (0.57) | KMT2AMAPTNPSR1MEN1RAB9A | |
| SCHEMBL29370463 | 0.85 | MAPT (0.57) | KMT2AMAPTNPSR1MEN1RAB9A | |
| SCHEMBL5563288 | 0.85 | MEN1 (0.50) | KMT2AMAPTMEN1RAB9ASMN1; SMN2 | |
| SCHEMBL6525254 | 0.84 | MAPT (0.62) | KMT2AMAPTNPSR1MEN1RAB9A | |
| SCHEMBL7045956 | 0.83 | KMT2A (0.53) | KMT2AMAPTNPSR1MEN1RAB9A | |
| SCHEMBL117243 | 0.83 | HCAR3 (0.50) | KMT2AMAPTNPSR1MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683092-B2 | Crystalline forms of antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683092-B2 | Crystalline forms of antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7683092-B2 | Crystalline forms of antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2010-03-23 | — | — | US | disclosed |
| EP-1858844-A4 | NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS | MERCK & CO INC (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20080221198-A1 | Novel Crystalline Forms of Antidiabetic Compounds | MERCK SHARP & DOHME CORP. | 2008-09-11 | — | — | US | disclosed |
| US-20080221198-A1 | Novel Crystalline Forms of Antidiabetic Compounds | MERCK SHARP & DOHME CORP. | 2008-09-11 | — | — | US | disclosed |
| US-20080221198-A1 | Novel Crystalline Forms of Antidiabetic Compounds | MERCK SHARP & DOHME CORP. | 2008-09-11 | — | — | US | disclosed |
| US-20080076810-A1 | Benzoureas Having Anti-Diabetic Activity | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| US-20080076810-A1 | Benzoureas Having Anti-Diabetic Activity | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| EP-1858844-A1 | NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS | Merck & Co., Inc. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006099077-A1 | NOVEL CRYSTALLINE FORMS OF ANTIDIABETIC COMPOUNDS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
| EP-1651234-A1 | COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014002-A1 | COMBINATION OF MGLUR2 ANTAGONIST AND ACHE INHIBITOR FOR TREATMENT OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| EP-1474416-A1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003066623-A1 | DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
| US-5236940-A | Administering for treatment of medical conditions associated with the effects of glutamate; glutamate-induced convulsions; schizophrenia; sleep disorders | RHONE-POULENC SANTE (FR) | 1993-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221198-A1 | Novel Crystalline Forms of Antidiabetic Compounds | FFAR2, PPARG, PPARA | KMT2A 1951/4885MAPT 2274/4885NPSR1 337/4885 |
| US-20080076810-A1 | Benzoureas Having Anti-Diabetic Activity | PPARD, PPARG, GPR119 | KMT2A 1230/4885MAPT 4720/4885NPSR1 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.